NASDAQ
LABT
Last Price
US $2.33
Valuation
Financial
Performance
Cash flow to debt coverage
Lakewood-Amedex Biotherapeutics Inc. Common Stock balance-sheet data unavailable; cash-flow debt coverage cannot be computed.
Free cash flow growth
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Debt-to-equity ratio
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Debt-to-equity trend
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Net debt to EBITDA
Lakewood-Amedex Biotherapeutics Inc. Common Stock has negative EBITDA, making leverage ratio unreliable
Interest coverage
Lakewood-Amedex Biotherapeutics Inc. Common Stock interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Profit margin growth
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Current ratio
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Return on assets
Lakewood-Amedex Biotherapeutics Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Lakewood-Amedex Biotherapeutics Inc. Common Stock's return on equity of 0.00%, is lower than 15.00%, indicating bad performance
Earnings quality
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Earnings stability
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Lakewood-Amedex Biotherapeutics Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Lakewood-Amedex Biotherapeutics Inc. Common Stock has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Revenue growth
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Return on invested capital
ROIC is unavailable for Lakewood-Amedex Biotherapeutics Inc. Common Stock; this check cannot be evaluated.
3-year revenue CAGR
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
Earnings yield (TTM)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to evaluate this check.
EBITDA Valuation
Lakewood-Amedex Biotherapeutics Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has insufficient data to calculate the PEG ratio.
Price-to-book ratio (FY)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Lakewood-Amedex Biotherapeutics Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $2.33
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.